The 12-month data from PRESTIGE was presented at LINC 2021 in January, showing sustained benefits up to one year. 18-month data is to be presented at VIVA in October this year, where it is anticipated that these benefits will be further sustained.

The findings have been published this week in a study titled “Retrospective Real World Comparative Effectiveness of Ovine Forestomach Matrix and Collagen/ORC in the Management of Diabetic Foot Ulcers” published in the ‘International Wound Journal.’

Study adds to a growing body of clinical evidence supporting the safety and efficacy of VivAer, a non-invasive, temperature-controlled radiofrequency device.

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.